Basic Information
| LncRNA/CircRNA Name | HOXD-AS1 |
| Synonyms | HAGLR, HOXD-AS1, Mdgt |
| Region | GRCh38_2:176164051-176188958 |
| Ensemble | ENSG00000224189 |
| Refseq | NR_033979 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | colorectal cancer |
| ICD-0-3 | C19.9 |
| Methods | qPCR, Western blot, Luciferase reporter assay etc |
| Sample | colorectal cancer tissues, cell lines (HCT116, CCD-112CoN) |
| Expression Pattern | up-regulated |
| Function Description | HOXD-AS1 was upregulated in CRC tissues and cell lines, and that overexpression of HOXD-AS1 was associated with poor prognosis in patients with CRC. Furthermore, knockdown of HOXD-AS1 inhibited cell proliferation, cell invasion, epithelial mesenchymal transition and stem cell formation in vitro,as well as tumor growth and metastasis in vivo. Mechanistically, HOXD-AS1 functioned as a competing endogenous RNA for miR-217. In conclusion, the present study demonstrated that HOXD-AS1 may promote CRC progression and metastasis by competing for miR-217. In addition, HOXD-AS1 may be considered an indicator of prognosis in patients with CRC. The present study confirmed that HOXD-AS1 could act as a ceRNA for miR-217. |
| Pubmed ID | 29749477 |
| Year | 2018 |
| Title | Long non-coding RNA HOXD-AS1 promotes tumor progression and predicts poor prognosis in colorectal cancer. |
External Links
| Links for HOXD-AS1 | GenBank HGNC NONCODE |
| Links for colorectal cancer | OMIM COSMIC |